S

Sanofi

Global pharma company; vaccines and R&D

Head of Immunology

Full-TimePosted on 10/21/2026Deadline 11/15/26
No salary listed
Expert
Bachelor's, MBA
Barangaroo, Australia
In Person
Business & Strategy

About the job

Requirements
  • Business Unit leadership experience in biopharmaceuticals, typically 3+ years, including managing a major or diverse Business Unit.
  • Experience in Immunology or a related therapeutic area.
  • Experience in sales and marketing leadership.
  • Experience partnering on market access strategies, ideally in a health technology assessment market.
  • Working knowledge of the Australian and New Zealand payer landscape and key stakeholders.
  • Knowledge of the Australian reimbursement system.
  • Experience serving on an enterprise or senior leadership team.
  • Solid understanding of business finance and accounting.
  • Understanding of clinical development, project management, and therapeutic area science.
  • Familiarity with omnichannel engagement in healthcare.
  • Transformational leadership and strategic thinking.
  • Financial acumen and sound business judgement.
  • A proven record of developing and growing talent.
  • Ability to collaborate, work inclusively, and influence across a matrix organisation.
  • A bachelor's degree in Science, Business, or a related field, or equivalent practical experience.
Responsibilities
  • Set, communicate, and oversee short- and long-term goals and priorities for the Business Unit across current and future indications in Australia and New Zealand.
  • Lead integrated Customer Engagement plans, including omnichannel engagement, that deliver value to healthcare professionals and patients.
  • Represent the needs of the ANZ market and customers in global and regional Brand Plans.
  • Develop and consolidate revenue and expense budgets and forecasts for current and future indications, and manage the Business Unit as cost centre owner.
  • Take accountability for sales target attainment and spend within budget.
  • Oversee launch excellence, including market analysis, positioning, market access strategy, messaging, forecasting, and lifecycle management.
  • Monitor Business Unit performance and drive adjustments where needed.
  • Partner with the Franchise Head, Brand Leads, and MCO colleagues to optimise performance.
  • Work with Medical Affairs, Regulatory, and Corporate Affairs to shorten lead time to market for future indications.
  • Coordinate with Australian, South Korean, and global Specialty Care cross-functional teams, including market access, regulatory, and medical teams.
  • Contribute to the success of the wider ANZ business as part of the Pharma ANZ Leadership Team.
  • Lead and empower the National Sales Manager and Marketing leaders, who in turn lead the sales and marketing organisations.
  • Build an inclusive, high-trust team culture where people can contribute and grow.
  • Attract, develop, and retain diverse talent, providing regular feedback and quality Individual Development Plans for team members.
  • Support team members' wellbeing, engagement, and performance in line with local policies.
  • Complete people leadership processes across the Business Unit.
Desired Qualifications
  • An MBA or postgraduate qualification.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...